(Total Views: 680)
Posted On: 11/17/2020 5:29:25 PM
Post# of 148984
IMO it won’t take long to utilize the network of sites we have been developing to fill post viral syndrome trials including Covid.
FDA will leave the porch light on for post viral, because it’s a no-brainer with our safety record.
That being said, I believe the FDA aren’t stalling anything. I think they are doing a respectable job “managing” divergent interests across a multitude of problematic diseases.
Will they prioritize the current doses of Leronlimab for Covid over Virologix for HIV? I would. I mean, duh...
At this point in time, Virologix is a quality of life issue, and Leronlimab is a life or death issue.
Perhaps post viral syndrome is off in the distance. But wait, add in Covid. Do people still die as Long-haulers?
And people wonder why we care about day 42 in CD-12? It starts to dovetail. As someone said yesterday causing me goosebumps, the thing is starting to spread wings.
FDA will leave the porch light on for post viral, because it’s a no-brainer with our safety record.
That being said, I believe the FDA aren’t stalling anything. I think they are doing a respectable job “managing” divergent interests across a multitude of problematic diseases.
Will they prioritize the current doses of Leronlimab for Covid over Virologix for HIV? I would. I mean, duh...
At this point in time, Virologix is a quality of life issue, and Leronlimab is a life or death issue.
Perhaps post viral syndrome is off in the distance. But wait, add in Covid. Do people still die as Long-haulers?
And people wonder why we care about day 42 in CD-12? It starts to dovetail. As someone said yesterday causing me goosebumps, the thing is starting to spread wings.
(2)
(1)Scroll down for more posts ▼
